2020 Metachromatic Leukodystrophy (MLD) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Metachromatic Leukodystrophy (MLD) pipeline report presents a comprehensive overview of the research and development of Metachromatic Leukodystrophy (MLD) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: One drug in Research phase, three drugs in pre-clinical phase, one drug in phase 1, two drugs in phase 2 and one drug in Pre-registration
As of February 2020, the Metachromatic Leukodystrophy (MLD) pipeline remains robust with 8 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Metachromatic Leukodystrophy (MLD) treatment. Diverse types of targeted therapies are being explored through clinical trials including AHR (Aryl hydrocarbon receptor) antagonist; Arylsulfatase replacements; glucocorticoid receptor; Gene transference.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Metachromatic Leukodystrophy (MLD) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Metachromatic Leukodystrophy (MLD) pipeline drugs profiled in the report include- AGT-183, ENX-201, HMI-202, MGTA-456, OTL-200, Drug for Metachromatic Leukodystrophy, TAK-611, CNS disorder therapies
As of February 2020, the Metachromatic Leukodystrophy (MLD) pipeline remains robust with 8 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Metachromatic Leukodystrophy (MLD) treatment. Diverse types of targeted therapies are being explored through clinical trials including AHR (Aryl hydrocarbon receptor) antagonist; Arylsulfatase replacements; glucocorticoid receptor; Gene transference.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Metachromatic Leukodystrophy (MLD) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Metachromatic Leukodystrophy (MLD) development
- Metachromatic Leukodystrophy (MLD) pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Metachromatic Leukodystrophy (MLD) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Metachromatic Leukodystrophy (MLD) pipeline candidates included
- Business overview and snapshot of all companies involved in Metachromatic Leukodystrophy (MLD) pipeline are included
- Latest market and pipeline developments are provided in the report
Metachromatic Leukodystrophy (MLD) pipeline drugs profiled in the report include- AGT-183, ENX-201, HMI-202, MGTA-456, OTL-200, Drug for Metachromatic Leukodystrophy, TAK-611, CNS disorder therapies
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Metachromatic Leukodystrophy (MLD) Condition
2.3 Metachromatic Leukodystrophy (MLD) Pipeline Snapshot, 2020
2.4 Companies investing in Metachromatic Leukodystrophy (MLD) pipeline therapeutics
2.5 Phase wise Metachromatic Leukodystrophy (MLD) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Metachromatic Leukodystrophy (MLD) Pipeline Products
2.7 Route of Administration of Metachromatic Leukodystrophy (MLD) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 ArmaGen Inc Overview, Contacts and ASD Pipeline Drugs
3.2 EnhanX Biopharm Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Homology Medicines Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Magenta Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Neuway Pharma GmbH Overview, Contacts and ASD Pipeline Drugs
3.6 Orchard Therapeutics Plc Overview, Contacts and ASD Pipeline Drugs
3.7 Recursion Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Takeda Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 AGT-183 Drug Details
4.1.1 AGT-183 Current Status
4.1.2 AGT-183 Drug Overview
4.1.3 AGT-183 Mechanism of Action
4.1.4 AGT-183 Licensing/Collaboration Companies
4.1.5 AGT-183 Clinical Trials
4.2 ENX-201 Drug Details
4.2.1 ENX-201 Current Status
4.2.2 ENX-201 Drug Overview
4.2.3 ENX-201 Mechanism of Action
4.2.4 ENX-201 Licensing/Collaboration Companies
4.2.5 ENX-201 Clinical Trials
4.3 HMI-202 Drug Details
4.3.1 HMI-202 Current Status
4.3.2 HMI-202 Drug Overview
4.3.3 HMI-202 Mechanism of Action
4.3.4 HMI-202 Licensing/Collaboration Companies
4.3.5 HMI-202 Clinical Trials
4.4 MGTA-456 Drug Details
4.4.1 MGTA-456 Current Status
4.4.2 MGTA-456 Drug Overview
4.4.3 MGTA-456 Mechanism of Action
4.4.4 MGTA-456 Licensing/Collaboration Companies
4.4.5 MGTA-456 Clinical Trials
4.5 OTL-200 Drug Details
4.5.1 OTL-200 Current Status
4.5.2 OTL-200 Drug Overview
4.5.3 OTL-200 Mechanism of Action
4.5.4 OTL-200 Licensing/Collaboration Companies
4.5.5 OTL-200 Clinical Trials
4.6 Drug for Metachromatic Leukodystrophy Drug Details
4.6.1 Drug for Metachromatic Leukodystrophy Current Status
4.6.2 Drug for Metachromatic Leukodystrophy Drug Overview
4.6.3 Drug for Metachromatic Leukodystrophy Mechanism of Action
4.6.4 Drug for Metachromatic Leukodystrophy Licensing/Collaboration Companies
4.6.5 Drug for Metachromatic Leukodystrophy Clinical Trials
4.7 TAK-611 Drug Details
4.7.1 TAK-611 Current Status
4.7.2 TAK-611 Drug Overview
4.7.3 TAK-611 Mechanism of Action
4.7.4 TAK-611 Licensing/Collaboration Companies
4.7.5 TAK-611 Clinical Trials
4.8 CNS disorder therapies Drug Details
4.8.1 CNS disorder therapies Current Status
4.8.2 CNS disorder therapies Drug Overview
4.8.3 CNS disorder therapies Mechanism of Action
4.8.4 CNS disorder therapies Licensing/Collaboration Companies
4.8.5 CNS disorder therapies Clinical Trials
5. LATEST METACHROMATIC LEUKODYSTROPHY (MLD) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Metachromatic Leukodystrophy (MLD) Condition
2.3 Metachromatic Leukodystrophy (MLD) Pipeline Snapshot, 2020
2.4 Companies investing in Metachromatic Leukodystrophy (MLD) pipeline therapeutics
2.5 Phase wise Metachromatic Leukodystrophy (MLD) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Metachromatic Leukodystrophy (MLD) Pipeline Products
2.7 Route of Administration of Metachromatic Leukodystrophy (MLD) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 ArmaGen Inc Overview, Contacts and ASD Pipeline Drugs
3.2 EnhanX Biopharm Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Homology Medicines Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Magenta Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Neuway Pharma GmbH Overview, Contacts and ASD Pipeline Drugs
3.6 Orchard Therapeutics Plc Overview, Contacts and ASD Pipeline Drugs
3.7 Recursion Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Takeda Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 AGT-183 Drug Details
4.1.1 AGT-183 Current Status
4.1.2 AGT-183 Drug Overview
4.1.3 AGT-183 Mechanism of Action
4.1.4 AGT-183 Licensing/Collaboration Companies
4.1.5 AGT-183 Clinical Trials
4.2 ENX-201 Drug Details
4.2.1 ENX-201 Current Status
4.2.2 ENX-201 Drug Overview
4.2.3 ENX-201 Mechanism of Action
4.2.4 ENX-201 Licensing/Collaboration Companies
4.2.5 ENX-201 Clinical Trials
4.3 HMI-202 Drug Details
4.3.1 HMI-202 Current Status
4.3.2 HMI-202 Drug Overview
4.3.3 HMI-202 Mechanism of Action
4.3.4 HMI-202 Licensing/Collaboration Companies
4.3.5 HMI-202 Clinical Trials
4.4 MGTA-456 Drug Details
4.4.1 MGTA-456 Current Status
4.4.2 MGTA-456 Drug Overview
4.4.3 MGTA-456 Mechanism of Action
4.4.4 MGTA-456 Licensing/Collaboration Companies
4.4.5 MGTA-456 Clinical Trials
4.5 OTL-200 Drug Details
4.5.1 OTL-200 Current Status
4.5.2 OTL-200 Drug Overview
4.5.3 OTL-200 Mechanism of Action
4.5.4 OTL-200 Licensing/Collaboration Companies
4.5.5 OTL-200 Clinical Trials
4.6 Drug for Metachromatic Leukodystrophy Drug Details
4.6.1 Drug for Metachromatic Leukodystrophy Current Status
4.6.2 Drug for Metachromatic Leukodystrophy Drug Overview
4.6.3 Drug for Metachromatic Leukodystrophy Mechanism of Action
4.6.4 Drug for Metachromatic Leukodystrophy Licensing/Collaboration Companies
4.6.5 Drug for Metachromatic Leukodystrophy Clinical Trials
4.7 TAK-611 Drug Details
4.7.1 TAK-611 Current Status
4.7.2 TAK-611 Drug Overview
4.7.3 TAK-611 Mechanism of Action
4.7.4 TAK-611 Licensing/Collaboration Companies
4.7.5 TAK-611 Clinical Trials
4.8 CNS disorder therapies Drug Details
4.8.1 CNS disorder therapies Current Status
4.8.2 CNS disorder therapies Drug Overview
4.8.3 CNS disorder therapies Mechanism of Action
4.8.4 CNS disorder therapies Licensing/Collaboration Companies
4.8.5 CNS disorder therapies Clinical Trials
5. LATEST METACHROMATIC LEUKODYSTROPHY (MLD) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
